Table 7 Factors affecting occurrence of severe CRS by logistic regression analysis.

From: Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients

Items

Logistic regression model

P value

OR

95% CI

Lower

Higher

Univariate logistic regression

Age (≥18 vs. <18 years)

0.096

3.325

0.809

13.674

Gender (male vs. female)

0.721

1.269

0.343

4.696

Number of previous chemotherapies (≥4 vs. <4)

0.759

0.816

0.223

2.992

Refractory disease (yes vs. no)

0.005

8.250

1.895

35.910

Relapsed disease (yes vs. no)

0.148

0.174

0.016

1.857

Bone marrow blasts (≥5% vs. <5%)

0.675

1.382

0.305

6.255

Extramedullary disease (yes vs. no)

0.334

0.525

0.142

1.943

CNSL (yes vs. no)

0.334

0.525

0.142

1.943

BCR/ABL1 (positive vs. negative)

0.256

0.417

0.092

1.888

SH2B3 mutation (positive vs. negative)

0.171

0.350

0.078

1.573

PAX5 mutation (positive vs. negative)

0.236

0.430

0.106

1.739

WBC (≥30 × 109/L vs. <30 × 109/L)

0.082

0.300

0.077

1.163

Lymphodepletion regimens (Flu + Cy vs. non-Flu + Cy)

0.784

1.214

0.303

4.867

CAR-T cells (anti-CD19 + CD22 vs. anti-CD19)

0.792

0.833

0.215

3.230

Multivariate logistic regression

Refractory disease (yes vs. no)

0.005

12.599

2.187

72.587

WBC (≥30 × 109/L vs. <30 × 109/L)

0.047

0.169

0.029

0.978

  1. Factors affecting occurrence of severe CRS were determined by univariate and multivariate Logistic regression analysis with Forward Stepwise (Conditional) method. P value <0.05 was considered significant.
  2. CRS cytokine release syndrome, CR complete remission, MRD minimal residual disease, CNSL central nervous system leukemia, WBC white blood cell, Flu fludarabine, Cy cyclophosphamide, CAR-T chimeric antigen receptor T cells, OR odds ratio, CI confidence interval.
Back to article page